In the March quarter, Sun Pharma reported strong revenue and profit growth, reflecting solid performance in its domestic formulations segment. However, the company experienced pressure on EBITDA margins, primarily due to increased investments and reduced milestone income. Looking ahead to fiscal year 2027, Sun Pharma anticipates range-bound margins and a moderation in revenue growth. This outlook is driven by planned specialty product launches and continued research and development spending. While the domestic market remains robust, the recovery in the US segment is expected to be gradual, indicating a cautious growth trajectory for the company. Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income.